Device Trial Radar · NCT06991270
OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Oct 8, 2025
Primary completion
Dec 1, 2026
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Sight Sciences, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 27, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To gain early evidence of safety and assess the effectiveness of the intraocular pressure (IOP)-lowering effectiveness of the OMNI 3.0 Surgical System in primary open-angel glaucoma (POAG).
Conditions
- Primary Open Angle Glaucoma
Interventions
OMNI 3.0 Surgical SystemDevice
Canaloplasty and trabeculotomy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary Effectiveness EndpointTime frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Panama Eye Center
Panama City, Panama
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.